Drugs / BAY2666605
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT04809805 | Apr 2021 → Nov 2022 | metastatic melanoma | Bayer | Terminated | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | BAY2666605 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04809805 ↗ |
| Route | Oral | “All of the participants will take BAY2666605 by mouth as either a liquid or as tablets.” NCT04809805 ↗ |
| Target | PDE3A | “BAY2666605 triggers the formation of a complex of two proteins called SLFN12 and PDE3A.” NCT04809805 ↗ |
| Target | SLFN12 | “BAY2666605 triggers the formation of a complex of two proteins called SLFN12 and PDE3A.” NCT04809805 ↗ |